| Ytd | ||
| 1y |
| Open | Prev Close | 1.93 | Low | High | Mkt Cap | 59.31M | |||
| Vol | 0.00 | Avg Vol | 1.19M | EPS | -0.43 | P/E | -4.44 | Forward P/E | -0.91 |
| Beta | 0.92 | Short Ratio | 17.89 | Inst. Own | 23.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.41 | 200-d Avg | 0.91 | 1yr Est | 6.75 |
DRRX News
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis wit
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis wit
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE
Durect (DRRX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate
Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transac
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breache
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designa
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designa
Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate
Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AH
CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage b
CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced t
The article presents new trial data, including subgroup analyses and liver biomarkers, which have gu
Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about t
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9,
On Wednesday, 311 stocks hit new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018